Trizytek FDA Approval Status
FDA Approved: No
Brand name: Trizytek
Generic name: liprotamase
Company: Eli Lilly and Company
Treatment for: Pancreatic Exocrine Dysfunction
Trizytek (liprotamase) is a non-porcine derived enzyme replacement therapy in development for patients with pancreatic insufficiency. The FDA issued a complete response letter for liprotamase in April 2011.
Development timeline for Trizytek
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.